Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
6.85
-0.13 (-1.86%)
Mar 9, 2026, 2:08 PM EDT - Market open
Aligos Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Mar '26 Mar 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 42 | 57 | 148 | 50 | 41 | 506 | |
| Market Cap Growth | -45.53% | -61.21% | 197.20% | 21.95% | -91.94% | -52.00% | |
| Enterprise Value | -30 | -36 | 82 | -9 | -88 | 276 | |
| Last Close Price | 6.98 | 9.32 | 39.84 | 16.60 | 23.82 | 296.75 | |
| PS Ratio | 19.65 | 26.24 | 37.48 | 3.20 | 2.93 | 116.05 | |
| PB Ratio | 0.81 | 1.07 | -5.10 | 0.54 | 0.39 | 2.74 | |
| P/TBV Ratio | 0.80 | 1.07 | - | 0.54 | 0.39 | 2.74 | |
| EV/Sales Ratio | - | - | 20.81 | - | - | 63.34 | |
| Debt / Equity Ratio | 0.10 | 0.10 | -0.29 | 0.12 | 0.12 | 0.08 | |
| Net Debt / Equity Ratio | -1.36 | -1.36 | 1.68 | -1.35 | -1.09 | -0.95 | |
| Net Debt / EBITDA Ratio | 0.83 | 0.83 | 0.55 | 1.45 | 1.19 | 1.41 | |
| Net Debt / FCF Ratio | 0.88 | 0.88 | 0.60 | 1.58 | 1.41 | 1.51 | |
| Asset Turnover | 0.03 | 0.03 | 0.04 | 0.10 | 0.07 | 0.02 | |
| Quick Ratio | 3.67 | 3.67 | 2.62 | 5.68 | 3.80 | 4.90 | |
| Current Ratio | 3.90 | 3.90 | 2.86 | 5.90 | 4.03 | 5.25 | |
| Return on Equity (ROE) | -196.91% | -196.91% | -415.84% | -89.48% | -66.55% | -63.41% | |
| Return on Assets (ROA) | -69.33% | -69.33% | -50.29% | -36.63% | -31.92% | -32.04% | |
| Return on Capital Employed (ROCE) | -130.70% | -130.70% | -184.40% | -68.50% | -85.90% | -65.30% | |
| Earnings Yield | -56.33% | -42.18% | -88.73% | -176.22% | -235.41% | -25.37% | |
| FCF Yield | -193.10% | -144.62% | -54.69% | -158.81% | -196.90% | -23.04% | |
| Buyback Yield / Dilution | -57.79% | -57.79% | -144.38% | -50.10% | -7.12% | -299.03% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.